Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

LILRB1 / ILT-2 / CD85j Antibody [VMP55]

In Stock
Catalog Number Formulation Size Price
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol
Flow Cytometry (Flow)
1-2ug/million cells
Immunofluorescence (IF)
Western Blot (WB)


Leukocyte immunoglobulin-like receptors (LIRs) are members of the immunoglobulin superfamily of glycoproteins and are predominantly expressed by monocytes, B cells, dendritic cells, natural killer (NK) cells, peripheral blood leukocytes and tissues such as placenta, lung and liver. Immunoglobulin-like transcript 2 (ILT-2), also known as CD85 or MIR7, is a 650 amino acid glycoprotein that contains a 23 amino acid signal peptide, 4 extracellular C2-type IGSF domains and 4 intracellular ITIM motifs. ILT-2 can bind major histocompatability (MHC) class I molecules and inhibit cell termination by natural killer (NK) and T cells, and inhibit Ca2+ mobilization in myeloid cells triggered through the B cell antigen receptor and histocompatibility leukocyte antigens (HLA)-DR. ILT-2 contains four putative cytoplasmic tyrosine-based inhibitory motifs and upon tyrosine phosphorylation, associates with the tyrosine phosphatase SHP-1.

Product Properties & Targets

Antibody Type
Species Reactivity
Research Areas
Isotype / Light Chain
IgG1 / Kappa
Cellular Localization
Cell membrane, Secreted
Gene Name
Positive Control
IB4 or K-562 cells. Human PBMCs.
Hairy cell leukemia cells
Alternate Names
Leukocyte immunoglobulin-like receptor subfamily B member 1, CD85 antigen-like family member J, Immunoglobulin-like transcript 2, Monocyte/macrophage immunoglobulin-like receptor 7, CD85 antigen; CD85j antigen; Ig like transcript 2; immunoglobulin like transcript 2 (ILT2); leukocyte Ig like receptor 1; Leukocyte immunoglobulin like receptor 1; leukocyte immunoglobulin like receptor subfamily B member 1 soluble isoform; LILRB1; LIR1; Monocyte/macrophage immunoglobulin like receptor 7 (MIR7); PIRB

Database Links

Entrez Gene ID

Additional Information

Chromosome Location
Mol. Weight of Antigen


  • Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11907092, PubMed:9285411, PubMed:9842885). Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (PubMed:16455647). Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells (PubMed:29262349, PubMed:19304799). Reprograms B cells toward an immune suppressive phenotype (PubMed:24453251).

Key References

  • Kim, J.S., et al. 2004. Human cytomegalovirus UL18 alleviated human NK-mediated swine endothelial cell lysis. Biochem. Biophys. Res. Commun. 315: 144-150.

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.


This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.


There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.


There are no reviews yet.

Be the first to review “LILRB1 / ILT-2 / CD85j Antibody”

Your email address will not be published. Required fields are marked *


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.